**Heidelberg, Germany
December 8–9 2016**

**FACULTY**

1. Ernst Hund (co-chair) – Heidelberg
2. Arnt Kristen (co-chair) – Heidelberg
3. Ute Hegenbart – Heidelberg
4. Jan Purrucker – Heidelberg
5. Christoph Roecken – Kiel, Germany
6. Fabian aus dem Siepen – Heidelberg
7. Jennifer Kollmer – Heidelberg
8. Christoph Kimmich – Heidelberg
9. Isabel Conceição – Lisbon, Portugal
10. Marco Ochs – Heidelberg

**DELEGATES**

* Delegates will be more junior physicians with limited or no exposure to
TTR-amyloidosis (ATTR). Delegates should not have attended past meetings on ATTR

**OBJECTIVES**

* Pfizer have developed the Masterclass series to provide an opportunity to increase disease awareness and diagnostic skills amongst less experienced physicians – those that may have no or little awareness of ATTR and, specifically, TTR-FAP.
* The course should equip clinicians with the latest information on recognising and diagnosing ATTR patients to facilitate best practice. In particular, the agenda should feature practical sessions.

**AGENDA**

**Pre-meeting webex slide reviews**

**Arrivals on morning of December 7th**

**Presentation rehearsals on December 7th**

|  |  |  |
| --- | --- | --- |
| **Time**  | **Topic**  | **Speaker** |
| **09.30**5 mins | **Welcome and introduction*** Introduction to the meeting objectives and faculty overview
 | Ernst Hund & Arnt Kristen |
| **09.35**10 mins | **Amyloidosis at Heidelberg*** Overview of the history, structure and key objectives of the Heidelberg amyloidosis centre
 | Ute Hegenbart |
| **ATTR: An Overview****Moderator: Arnt Kristen** |
| **09.45**30 mins | **Clinical manifestations of ATTR*** Introduction to mechanism of disease of ATTR, and overview of phenotypic variability
* Overview of epidemiology, prevalence and genetics of ATTR and its distinguishing features
 | Ernst Hund |
| **10.15**15 mins | **The natural history of ATTR** * Overview of what is known about disease progression to date in untreated patients, including published data from THAOS
* Include date on impact on quality of life + potential to present video on quality of life from Bulgaria
 | Arnt Kristen |
| **10.30**10 mins | Q&A session |  |
| **10.40** *- Coffee break* |
| **ATTR: Symptomatology and diagnosis****Moderator: Ernst Hund** |
| **11.00**25 mins | **Neurological manifestations and evaluations*** Neurological manifestations of ATTR – description, initial presentation and how to evaluate
* Monitoring and follow-up of asymptomatic carriers and tools used at Heidelberg that can support recognition of the earliest signs and symptoms of disease. May include: electrophysiology, QSART, Sudoscan, nerve fibre density
 | Jan Purrucker |
| **11.25**25 mins | **Cardiac manifestations and evaluations** * Overview of cardiac manifestations of ATTR
* Prevalence and prognosis of genotypes associated with more severe TTR-cardiomyopathy in ATTR patients
* Early cardiac signs and symptoms in non-V30M patients that may suggest amyloid involvement
 | Arnt Kristen |
| **11.50**25 mins | **Early diagnosis: Recognising “red flag” signs and symptoms of ATTR*** ATTR is typically diagnosed late and overlapping symptomatology is linked to frequent misdiagnosis
* Benefits of early diagnosis
* Overview of red flag tool and the key signs and symptoms that physicians should look for
 | Isabel Conceição |
| **12.15**30 mins | **Management options for TTR-FAP*** Overview of treatment options for individuals with TTR-FAP
 | Isabel Conceição |
| **12.45** *- Lunch* |

|  |
| --- |
| **Practical session at Heidelberg hospital** |
| **14.00** | *Transfer to Heidelberg hospital* |
| ~30 mins per session with 10 mins changeover | **Heidelberg hospital visit: Clinical practice session** *Each participant will attend two sessions, and will select their preferred options when registering for the meeting. A coffee break will be provided in between the two sessions.* |
| **14.15 - Clinical practice 1*** Session A: Cardiac MRI
* Session B: Neuro MRI
 | Fabian aus dem Siepen Jennifer Kollmer |
| **15.00 - Clinical practice 1*** Session C: Echocardiography
* Session D: Fat biopsy
 | Marco Ochs Christoph Kimmich |
| **15.30** | *Close of day 1 - Close of day 1 – shuttle transfer back to hotel* |

**Day two**

|  |
| --- |
|  |
| **09.15**20 mins | **Biopsy: challenges and best practice*** Briefly introduce biopsy in ATTR and the different options available
* Outline the challenges, such as the diffuse nature of amyloid, faced by pathologists diagnosing ATTR, and access to experienced pathologists
* What are the options for the histological/histochemical confirmation of amyloid deposits?
 | Christoph Roecken |
| **09.35**20 mins | **Finding and following asymptomatic carriers of a *TTR* gene mutation*** Guidance on the genetic counselling and follow-up of asymptomatic carriers and their families
 | Ute Hegenbart |
| **09.55**10 mins | **Session Q&A** |  |
| **10.05 –** *Coffee break* |
| **Avoiding misdiagnosis****Moderator: Ernst Hund** |
| **10.30**20 mins | **Common misdiagnoses*** Overview of the most common misdiagnoses of ATTR and the overlapping symptomology that contributes to this
* Discussion of key patient populations in whom the suspicion of ATTR should be increased
 | Ernst Hund |
| **10.50**30 mins | **Diagnostic pitfalls – example clinical cases*** Panel discussion of example clinical cases and the diagnostic pitfalls encountered. Each physician will present a past clinical case including multiple choice questions – the audience will be asked to vote on how they would respond and the panel will debate the best options sharing experience and knowledge for how this can support timely diagnosis
 | **Panel*** Jan Purrucker
* Fabian aus dem Siepen
 |
| **11.20**60 mins | **Case presentations from far and near*** Delegates are invited to present clinical cases or data from their centre for discussion with the panel
 |
| **12.30 - *Meeting close*** |